BX 471

Drug Profile

BX 471

Alternative Names: BAY 865047; CCR1 - Bayer Healthcare; CCR1 antagonist - Bayer Healthcare; SH T 04268H; ZK-811752

Latest Information Update: 21 Mar 2011

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals Inc.
  • Class Phenylurea compounds; Piperidines; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action CCR1 receptor antagonists; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Endometriosis; Multiple myeloma; Multiple sclerosis; Psoriasis

Most Recent Events

  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
  • 04 Apr 2007 Berlex Inc has been acquired by Bayer HealthCare (MR 9074204)
  • 29 Dec 2006 Schering AG is now called Bayer Schering Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top